$ABUS - I wouldnt be surprised for a jumpNASDAQ:ABUS - I wouldnt be surprised for a jump
Supported by fundamentals parameters
Good luck
Next report date
—
Report period
—
EPS estimate
—
Revenue estimate
—
−0.408EUR
−66.00 MEUR
16.44 MEUR
144.66 M
About Arbutus Biopharma Corporation
Sector
CEO
Michael J. McElhaugh
Headquarters
Warminster
Website
Employees (FY)
73
Founded
2005
FIGI
BBG000R8YZR8
Arbutus Biopharma Corp. is a clinical-stage biopharmaceutical company, which engages in developing novel therapeutics that target specific viral diseases. It focuses on the Hepatitis B virus, SARS-CoV-2, and other coronaviruses. The company was founded on October 6, 2005 and is headquartered in Warminster, PA.
Weekly Chart for ABUSIt seems ABUS is preparing for a big move. Weekly Chart is strong, over the 200w,100w and 50w MAV
ABUS - Breakout AttemptAttempting to breakout of a large down channel
Price has already moved out of it.
Bars pattern placed shows my thoughts of a spike out of the down channel and the bulls taking control.
If this does not occur assume bear control still in play.
POTENTIAL BULLISHPrice is currently squeezing, with a 50/50 chance of breaking above or below. So, all we have to do now is wait for a bullish candle to appear and break above USD4.50 with strong bullish momentum as a final confirmation.
ABUS - Similarities to Prior RunIn this post various similarities are displayed, corresponding to the same color
Both double bottoms on 1.618 (in yellow)
Both tops at 1.618 (in red)
The positioning above the 200 day moving average as of current is also an extremely bullish sign
ABUS about to go up due to Patent on MRNA... Interesting... Lets hope there is news release.. I don't know for certain if its only the patent news but I am confident on my TA. DO your own DD!
short analysisBecause of the convergence we see in the chart and the RSI, and the gray support range that indicates the fall to that range has not been seen, we will probably see that the chart experiences some re-fall. If the pull back up, we will have price growth up to the gray resistance range. And God knows
#ABUS to 4.91 Climbing to New Target by 16%Sector: Health Technology
Industry: Biotechnology
Arbutus Biopharma Corp. is a biopharmaceutical company. It engages in discovering, developing and commercializing a cure for patients suffering from chronic Hepatitis B virus infection. The company was founded in 2007 and is headquartered in Warmins
See all ideas
Trade directly on the supercharts through our supported, fully-verified and user-reviewed brokers.
Frequently Asked Questions
Depending on the exchange, the stock ticker may vary. For instance, on FWB exchange ARBUTUS BIOPHARMA stocks are traded under the ticker I9DN.
We've gathered analysts' opinions on ARBUTUS BIOPHARMA future price: according to them, I9DN price has a max estimate of 4.62 EUR and a min estimate of 3.70 EUR. Watch I9DN chart and read a more detailed ARBUTUS BIOPHARMA stock forecast: see what analysts think of ARBUTUS BIOPHARMA and suggest that you do with its stocks.
I9DN reached its all-time high on Oct 6, 2014 with the price of 23.800 EUR, and its all-time low was 0.766 EUR and was reached on Oct 31, 2019. View more price dynamics on I9DN chart.
See other stocks reaching their highest and lowest prices.
See other stocks reaching their highest and lowest prices.
Yes, you can track ARBUTUS BIOPHARMA financials in yearly and quarterly reports right on TradingView.
ARBUTUS BIOPHARMA is going to release the next earnings report on Aug 1, 2024. Keep track of upcoming events with our Earnings Calendar.
I9DN earnings for the last quarter are −0.09 EUR per share, whereas the estimation was −0.10 EUR resulting in a 9.09% surprise. The estimated earnings for the next quarter are −0.09 EUR per share. See more details about ARBUTUS BIOPHARMA earnings.
ARBUTUS BIOPHARMA revenue for the last quarter amounts to 1.42 M EUR despite the estimated figure of 2.52 M EUR. In the next quarter revenue is expected to reach 1.63 M EUR.
I9DN net income for the last quarter is −16.57 M EUR, while the quarter before that showed −17.50 M EUR of net income which accounts for 5.32% change. Track more ARBUTUS BIOPHARMA financial stats to get the full picture.
No, I9DN doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
As of Jun 3, 2024, the company has 73.00 employees. See our rating of the largest employees — is ARBUTUS BIOPHARMA on this list?
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. ARBUTUS BIOPHARMA EBITDA is −72.89 M EUR, and current EBITDA margin is −422.41%. See more stats in ARBUTUS BIOPHARMA financial statements.
Like other stocks, I9DN shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade ARBUTUS BIOPHARMA stock right from TradingView charts — choose your broker and connect to your account.